Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Makoto NishioShuji MurakamiHiasto KawakamiKyoichi OkishioMotohiro TamiyaHaruki KobayashiDaichi FujimotoShunichi SugawaraToshiyuki KozukiYuko OyaHiroki IzumiTakayuki ShiroyamaMiyako SatouchiNoboru YamamotoShota KanameDaiko MatsuokaYohei OtakeTakao TakaseTaro SembaKoichi AzumaPublished in: Cancer research communications (2024)
This phase II part of a phase Ib/II study assessed liposomal eribulin (E7389-LF) plus nivolumab in 34 patients with pretreated SCLC; 8 of 33 evaluable patients (including 6/27 pretreated with ICIs) had objective responses. The combination was tolerable; increases in vasculature-related biomarkers tended to correlate with responses.
Keyphrases
- phase ii
- open label
- phase ii study
- small cell lung cancer
- clinical trial
- end stage renal disease
- placebo controlled
- ejection fraction
- newly diagnosed
- chronic kidney disease
- phase iii
- metastatic breast cancer
- locally advanced
- prognostic factors
- drug delivery
- squamous cell carcinoma
- randomized controlled trial
- brain metastases
- patient reported
- rectal cancer